Summary

for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Official Title

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Keywords

Advanced Cancer Carcinoma, Non-Small-Cell Lung Nivolumab Dasatinib Antibodies, Monoclonal Relatlimab Ipilimumab BMS-986205 Nivolumab & Dasatinib Nivolumab & Relatlimab Nivolumab & Ipilimumab Nivolumab & BMS-986205

Eligibility

For people ages 18 years and up

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Advanced Non Small Cell Lung Cancer (NSCLC)
  • Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
  • Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
  • Must have at least 1 lesion with measurable disease

Exclusion Criteria:

  • Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment
  • Subjects who need daily oxygen therapy
  • People with autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Locations

  • University of California San Diego (UCSD) accepting new patients
    La Jolla California 92093 United States
  • Hoag Memorial Hospital Presbyterian accepting new patients
    Newport Beach California 92658 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
ID
NCT02750514
Phase
Phase 2
Study Type
Interventional
Last Updated